计算机辅助机械抽吸血栓清除装置治疗下肢髂股深静脉血栓的技术成功与短期结果
回顾性分析16例急性髂股深静脉血栓患者使用Lightning 12计算机辅助机械抽吸系统行血栓清除术,全部患者实现≥70%血栓减少,93.8%单次手术成功,中位失血量155.0 mL,无围术期并发症,随访1-8个月93.8%保持通畅。
要点
- 16例急性髂股深静脉血栓患者使用Lightning 12系统行计算机辅助机械抽吸血栓清除术。
- 全部患者实现≥70%血栓减少,93.8%单次手术成功,中位失血量155.0 mL,无输血。
- 随访1-8个月,93.8%患者治疗区域保持通畅,87.5%无复发症状。
核心结论
- 作者认为,使用Lightning 12系统的计算机辅助机械抽吸血栓清除术对于急性髂股深静脉血栓患者的血栓清除是安全的,单次手术技术成功率和症状缓解率高。
- 在本病例系列中,Lightning 12系统还与低失血量相关,无患者需要输血。
研究设计与样本
- 回顾性分析纳入2020年7月至2021年6月连续16例因髂股急性深静脉血栓接受计算机辅助机械抽吸血栓清除术的患者。
- 主要结局为多平面静脉造影确定的>70%血栓清除;次要结局包括单次治疗、抽吸期间失血量、术后输血需求、溶栓药物使用、出院前症状缓解及围术期并发症。
主要发现
- 16例患者平均年龄58.6岁(范围31-80岁),75.0%为女性,均表现为持续2至16天的疼痛和肿胀,无股青肿。
- 全部16例患者(100%)实现≥70%血栓减少,15例(93.8%)单次治疗成功,8例(50%)置入支架。
- 所有患者出院前症状缓解;中位失血量155.0 mL(四分位距95.0-187.5),无患者需要术后输血。
- 1例患者血栓清除后行血管成形术,1例患者(6.2%)接受辅助组织型纤溶酶原激活剂治疗;无患者发生术后急性肾衰竭,无围术期并发症。
- 随访1至8个月,16例中15例(93.8%)治疗髂股区域保持通畅,14例(87.5%)无复发症状。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The symptoms of deep vein thrombosis (DVT) include severe pain and swelling, and the complications can include post-thrombotic syndrome and recurrent venous thromboembolism. Aspiration thrombectomy (AT) treats arterial and venous disease by removing acute thrombus without reliance on thrombolytic agents but also has the potential to remove fresh blood. Intelligent aspiration is designed to minimize blood loss during AT by aspirating continuously in the thrombus but only intermittently when in a patent vascular segment with active flow. The Indigo System with Lightning 12 intelligent aspiration (Penumbra, Inc, Alameda, Calif) uses an automatic valve controlled by a proprietary computer algorithm to optimize thrombus removal and minimize blood loss. This computer-aided mechanical AT (CMAT) system was used for 16 consecutive patients. METHODS: The present retrospective review included 16 patients who had undergone CMAT for iliofemoral acute DVT from July 2020 to June 2021. The primary outcome was >70% thrombus removal as determined by multiplanar venography. The secondary outcomes included single-session therapy, blood loss during aspiration, the need for postprocedure blood transfusion, thrombolytic use, symptom resolution before discharge, and periprocedural complications. RESULTS: Sixteen patients (mean age, 58.6 years; range, 31-80 years; 75.0% women) had undergone CMAT with the Lightning 12 system. All the patients had presented with pain and swelling of 2 to 16 days in duration. No patient had presented with phlegmasia. Access was obtained via the popliteal (n = 11), posterior tibial (n = 3), small saphenous (n = 1), or soleal (n = 1) vein. Thrombus reduction of ≥70% was achieved for all 16 patients (100%). Single-session therapy was successful for 15 patients (93.8%). Eight patients (50%) had received stents. All patients had experienced symptom resolution before discharge. The median blood loss was 155.0 mL (interquartile range, 95.0-187.5), and no patient had required a postprocedure transfusion. One patient had undergone angioplasty after thrombectomy, and one patient (6.2%) had received adjunctive tissue plasminogen activator therapy. No patient had developed postoperative acute kidney failure. No periprocedural complications occurred. At 1 to 8 months of follow-up, 15 of the 16 patients (93.8%) had patency of the treated iliofemoral area, and 14 (87.5%) had no recurrent symptoms. CONCLUSIONS: These results suggest that CMAT using the Lightning 12 system is safe for clot removal for patients with acute iliofemoral DVT with a high rate of single-session technical success and symptom resolution. In the present case series, the Lightning 12 system was also associated with low blood loss, and no patient had required a blood transfusion.
引用
- Robertson B, Neville E, Muck A, et al. Technical success and short-term results from mechanical thrombectomy for lower extremity iliofemoral deep vein thrombosis using a computer aided mechanical aspiration thrombectomy device. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34823046. doi:10.1016/j.jvsv.2021.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。